secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tonix Pharmaceuticals Holding Corp. (TNXP)
CIK:        0001430306
Form:       8-K
Filed at:   2025-11-17T23:59:59+00:00
Accession:  0001999371-25-017964
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tonix launches TONMYA as first new fibromyalgia treatment in 15 years
---------------------------------------------------------------------

- TONMYA (cyclobenzaprine HCl sublingual tablets) now available by prescription nationwide.
- FDA approved Aug 15, 2025; first non-opioid once-daily bedtime analgesic for fibromyalgia.
- Phase 3 trials (nearly 1,000 patients) showed significant pain reduction vs placebo at 14 weeks.
- Most common side effects: oral hypoesthesia, somnolence, dry mouth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125017964/0001999371-25-017964-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1430306/000199937125017964/tnxp-8k_111725.htm
  HTML page:      https://secwatch.observer/filing/0001999371-25-017964

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer